Avian Influenza H5N1

Greffex Avian Influenza H5N1 Vaccine GREFLU/VIE™

Greffex Avian Influenza Vaccine GreFLU/VIE

Avian influenza, such as the avian influenza strain, once adapted to humans is likely to cause a deadly pandemic. From clinical experience, it has been deduced that approximately 50% of individuals infected with a contagious form will succumb to the disease. It has been further estimated that 90% of the US population will be infected within weeks from as few as 10 infected individuals in a major city.

These considerations led to the conclusion that “a large stockpile of an avian influenza-based vaccine containing potential pandemic influenza antigens, coupled with the capacity to rapidly make a better-matched vaccine based on human strains, would be the best strategy to mitigate pandemic influenza”. Indeed, all developed countries have begun to stockpile vaccines and vaccine precursor products for the avian H5N1 influenza virus. They have purchased enough material to cover on average 20% of their population replacing their stocks every other year. The World Health Organization aims to provide vaccines to major population centers in the remainder of the world (3% of the overall population). Together a need exists today for the production of about 180 million doses per year.

Greffex has produced the avian influenza vaccine GREFLU/VIE using its GREVAX Universal Platform. GREFLU/VIE has been undergoing preclinical testing and is entering the clinical trial phase. Manufacturing processes and clinical testing schemes of GREVAX influenza vaccines were discussed with the Food and Drug Administration. GREFLU/VIE is being developed in collaboration with the National Institute of Allergy and Infectious Diseases (NIAID).

In parallel, we have been working on other influenza vaccines, including a universal influenza vaccine, with the aim to provide broad immune protection prior to the emergence of a new influenza strain.

NIAID TESTS GREFFEX’S AVIAN FLU (H5N1) VACCINE
January 9, 2015

In studies sponsored by the National Institute of Allergy and Infectious Disease (NIAID), Greffex’s GreFluVie vaccine proved to be highly effective in protecting animals against H5N1. Mice were immunized in a prime/boost schedule before being challenged with a lethal dose of the pandemic avian influenza virus. At the low dose of 3×108 genome equivalents, the vaccine proved to be highly effective when given by intramuscular, subcutaneous, and intranasal routes. Intramuscular injection resulted in a rate of survival of 100%.